Company underscores support for the Administration's goal and outlines steps it has taken to hold down drug costs for consumers
CVS Health (NYSE: CVS) today submitted its comments in response to the Request for Information (RFI) on the Trump Administration's Blueprint to Lower Drug Prices. In a cover letter to Secretary of Health and Human Services (HHS) Alex Azar summarizing the full comments submitted to HHS, the company underscored support for the Administration's goals and emphasized the industry-leading steps it has taken to hold down drug costs and bring innovative solutions to market to help consumers. ... |